Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Consensus Recommendation of “Buy” from Brokerages

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has earned an average rating of “Buy” from the ten research firms that are currently covering the firm, MarketBeat Ratings reports. Ten research analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $67.75.

Several equities research analysts have recently issued reports on the stock. Royal Bank of Canada dropped their price objective on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research report on Thursday, January 9th. HC Wainwright lowered their price target on Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating for the company in a report on Friday, January 10th. BMO Capital Markets began coverage on Jasper Therapeutics in a research note on Friday, December 6th. They set an “outperform” rating and a $63.00 price objective on the stock. Finally, JMP Securities reiterated a “market outperform” rating and issued a $70.00 target price on shares of Jasper Therapeutics in a research note on Monday, January 6th.

Jasper Therapeutics Price Performance

Shares of NASDAQ:JSPR opened at $5.70 on Friday. The business has a 50-day moving average of $17.66 and a two-hundred day moving average of $19.03. The firm has a market capitalization of $85.50 million, a PE ratio of -1.20 and a beta of 2.18. Jasper Therapeutics has a 12 month low of $5.25 and a 12 month high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR) last issued its earnings results on Thursday, November 7th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.15). As a group, research analysts anticipate that Jasper Therapeutics will post -4.47 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets increased its holdings in Jasper Therapeutics by 208.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock worth $47,000 after purchasing an additional 1,698 shares during the last quarter. Wolff Wiese Magana LLC acquired a new stake in shares of Jasper Therapeutics during the third quarter worth approximately $59,000. MetLife Investment Management LLC increased its stake in shares of Jasper Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock worth $129,000 after buying an additional 3,873 shares during the last quarter. Rhumbline Advisers acquired a new stake in Jasper Therapeutics in the second quarter valued at $300,000. Finally, Jane Street Group LLC bought a new position in Jasper Therapeutics during the 3rd quarter valued at $251,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.